Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics

Journal: Science Translational Medicine

Published: 2020-06-24

DOI: 10.1126/scitranslmed.aay6570

Affiliations: 17

Authors: 20

Go to article
Institutions Share
Oxford Big Data Institute (BDI), United Kingdom (UK) 0.21
Stanley Center for Psychiatric Research, Broad Institute, United States of America (USA) 0.16
Estonian Genome Center, UT, Estonia 0.15
Oxford Wellcome Trust Centre for Human Genetics, United Kingdom (UK) 0.09
Oxford Nuffield Department of Population Health (NDPH), United Kingdom (UK) 0.06
Oxford MRC Population Health Research Unit (MRC PHRU), United Kingdom (UK) 0.06
Psychiatric and Neurodevelopmental Genetics Unit (PNGU), MGH, United States of America (USA) 0.04
Institute of Genomics, UT, Estonia 0.04
Program in Medical and Population Genetics, Broad Institute, United States of America (USA) 0.03
Department of Epidemiology and Biostatistics, PKU, China 0.03
Peking University Health Science Center (PUHSC), PKU, China 0.03
MRC Integrative Epidemiology Unit (IEU), UoB, United Kingdom (UK) 0.03
Bristol Medical School: Population Health Sciences, UoB, United Kingdom (UK) 0.03
NIHR Oxford Biomedical Research Centre (OxBRC), United Kingdom (UK) 0.02
John Radcliffe Hospital, United Kingdom (UK) 0.02
Analytic and Translational Genetics Unit (ATGU), MGH, United States of America (USA) 0.02
UMC Section Genetics, Netherlands 0.02